Use of Serum Homocysteine to Predict Cardiovascular Disease in Korean Men with or without Metabolic Syndrome
Journal of Korean Medical Science, 05/04/2012
The results of this study show that the presence of metabolic syndrome (MetS) needs to be considered when using homocysteine (Hcy) levels for predicting cardiovascular disease (CVD).
The authors conducted a case–control study, including 138 CVD and 290 non–CVD age–matched control subjects.
The subjects were divided into four subgroups: 34 CVD/MetS, 104 CVD, 77 MetS, and 213 normal subgroups.
The mean Hcy was significantly higher, whereas HDL and intake of vitamin B1 and B2 were lower in the CVD group (P < 0.05) than non–CVD group.
When compared to the control group, subjects with CVD/MetS, CVD and MetS exhibited high Hcy levels, with the highest observed in the CVD/MetS subgroup (P < 0.001).
Multivariate stepwise linear regression between CVD and markers of CVD showed Hcy significantly correlated with CVD (P < 0.05).
To predict CVD based on Hcy, Hcy threshold of 11.72 µM in non–MetS subjects had an area under the curve (AUC) of 0.664 (95% CI 0.598–0.731).
In MetS subjects, the AUC was 0.618 and Hcy threshold was 13.32 µM (95% CI 0.509–0.726).